<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02088645</url>
  </required_header>
  <id_info>
    <org_study_id>KFS-3170-02-2013</org_study_id>
    <nct_id>NCT02088645</nct_id>
  </id_info>
  <brief_title>177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.</brief_title>
  <acronym>Lumed</acronym>
  <official_title>177Lu-PP-F11N for Receptor Targeted Therapy and Imaging (Theranostics) of Metastatic Medullary Thyroid Cancer - a Pilot and a Phase I Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Krebsforschung Schweiz, Bern, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center for Proton Therapy, Paul Scherrer Institute, Villigen,Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Zürich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the use of 177Lu-PP-F11N for imaging and therapy of&#xD;
      patients with advanced medullary thyroid carcinoma (MTC). 177Lu-PP-F11N is a gastrin&#xD;
      analogon, binding to cholecystokinin-2 receptors. This receptors show an overexpression on&#xD;
      more than 90 % of medullary thyroid carcinomas.&#xD;
&#xD;
      In the pilot (phase 0) study investigators will correlate the tumour detection rate with the&#xD;
      surgery and histology (proof of concept study). Furthermore, kidney protection and dosimetry&#xD;
      studies will be performed in order to determine the kidney protection protocol and starting&#xD;
      activity for the dose escalation study in the following, dose escalation (phase I) study. In&#xD;
      the phase I study investigators will determinate the maximum tolerated dose of 177Lu-PP-F11N&#xD;
      in patients with MTC. Furthermore, correlation with tumour radiation dose and treatment&#xD;
      response as well as organ radiation doses and maximal tolerated dose will be performed in&#xD;
      order to allow prospective individual patient tailored therapy planning. In the phase I&#xD;
      study, participation is additionally possible for patients with well differentiated GEP-NET&#xD;
      (grade 1-3) with a Ki67 index of up to 55% or NET of the lung or thymus (grade 1 and 2).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 0: Scintigraphic visualisation rate</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Phase 0 study: Evaluation of the scintigraphic visualisation of metastases after test injection, verification of 177Lu-PP-F11N uptake in metastases and correlation with surgery/histology if possible (poof of principle study).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I: Maximum tolerated dose</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Phase I study: Determination of the maximum tolerated dose (MTD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 0: Tumour-to-kidney radiation doses</measure>
    <time_frame>8 and 16 weeks</time_frame>
    <description>Evaluation of the kidney radiation dose and the tumour-to-kidney radiation dose ratios with and without kidney protection (Physiogel). Composite measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 0: Radiation doses</measure>
    <time_frame>8 and 16 weeks</time_frame>
    <description>Calculation of tumour and organ radiation doses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 0: In vivo stability</measure>
    <time_frame>8 and 16 weeks</time_frame>
    <description>Evaluation of in vivo stability of 177Lu-PP-F11N.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 0: Metabolites</measure>
    <time_frame>8 and 16 weeks</time_frame>
    <description>Measurement of the metabolites of 177Lu-PP-F11N with and without Physiogel infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Side reactions</measure>
    <time_frame>8, 16 and 24 weeks</time_frame>
    <description>Evaluation of side reactions of 177Lu-PP-F11N.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Biochemical response</measure>
    <time_frame>For the duration of 24 months.</time_frame>
    <description>Evaluation of biochemical response (decrease of calcitonin and calculation of calcitonin doubling time).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Morphological response</measure>
    <time_frame>0, 3 and 12 months</time_frame>
    <description>Evaluation of morphological therapy response (RECIST criteria).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Tumour detection rate</measure>
    <time_frame>8, 16 and 24 weeks</time_frame>
    <description>Determination of the tumour detection rate and correlation with surgery/histology, if possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Organ radiation doses</measure>
    <time_frame>8, 16 and 24 weeks</time_frame>
    <description>Calculation of organ radiation doses after therapy and correlation with the determined MTD (composite measure).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Overall survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Determination of overall survival of patients after therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: In vivo stability</measure>
    <time_frame>8, 16 und 24 weeks</time_frame>
    <description>Evaluation of in vivo stability of 177Lu-PP-F11N.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Metabolites</measure>
    <time_frame>8, 16 and 24 weeks</time_frame>
    <description>Measurement of the metabolites of 177Lu-PP-F11N.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Thyroid Cancer, Medullary</condition>
  <condition>Neuroendocrine Tumor of the Lung Grade 1 and 2</condition>
  <condition>Neuroendocrine Tumor of the Thymus Grade 1 and 2</condition>
  <condition>Neuroendocrine Tumor GEP Grade 1-3</condition>
  <arm_group>
    <arm_group_label>Phase 0: One arm; Phase I: One arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 0: 6 patients, intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N with and without Physiogel (crossover)&#xD;
Phase I: expected 12 - 18 patients, intravenous application of max. 6 x 7-8 GBq 177Lu-PP-F11N (increasing number of applications by one in groups of three patients). All patients with or without Physiogel, depending on the results of the phase 0 study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>177Lu-PP-F11N</intervention_name>
    <arm_group_label>Phase 0: One arm; Phase I: One arm</arm_group_label>
    <other_name>Minigastrin analogue</other_name>
    <other_name>Gastrin analogue</other_name>
    <other_name>Cholecystokinin-2 receptor ligand</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Phase 0 study&#xD;
&#xD;
          -  Advanced MTC with elevated levels of calcitonin (&gt; 100 pg/ml) and/or&#xD;
             calcitonin-doubling time &lt; 24 months before or after total thyroidectomy or&#xD;
&#xD;
          -  Patients with well differentiated GEP-NET (grade 1-3) with a Ki67 index of up to 55%&#xD;
             or NET of the lung or thymus (grade 1 and 2) with low or missing expression of&#xD;
             SST2-receptor and progressive disease within the last 6 months according to RECIST 1.1&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Phase I study&#xD;
&#xD;
          -  Diagnostic, contrast medium enhanced CT scan neck/thorax/abdomen, not older than 4&#xD;
             weeks&#xD;
&#xD;
          -  Advanced MTC with elevated levels of calcitonin (&gt; 100 pg/ml) and/or&#xD;
             calcitonin-doubling time &lt; 24 months before or after total thyroidectomy- Age &gt; 18&#xD;
             Years&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  Curative surgical therapy not possible&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Phase 0 study&#xD;
&#xD;
          -  Medication with Vandetanib 3 weeks before the study and during the study&#xD;
&#xD;
          -  Renal failure (calculated glomerular filtration rate (GFR) &lt; 60 ml/min per 1.73 m2&#xD;
             body surface).&#xD;
&#xD;
          -  Bone marrow failure (thrombocytes &lt; 70 000/μl, leucocytes &lt; 2 500/μl, hemoglobin &lt; 8&#xD;
             g/dl).&#xD;
&#xD;
          -  Pregnancy and breast feeding&#xD;
&#xD;
          -  Knows allergic reaction on Physiogel or other gelatine products&#xD;
&#xD;
          -  Known, serious side reaction in the case of a former application of pentagastrin&#xD;
&#xD;
          -  Active, second malignancy oder remission after second malignancy &lt; 5 years&#xD;
&#xD;
        Phase I study&#xD;
&#xD;
          -  Medication with Vandetanib 3 weeks before the study and during the study&#xD;
&#xD;
          -  Renal failure (calculated GFR &lt; 50 ml/min per 1.73 m2 body surface).&#xD;
&#xD;
          -  Bone marrow failure (thrombocytes &lt; 100 000/μl, leucocytes &lt; 3 000/μl, hemoglobin &lt; 10&#xD;
             g/dl).&#xD;
&#xD;
          -  Pregnancy and breast feeding&#xD;
&#xD;
          -  Known, serious side reaction in the case of a former application of pentagastrin&#xD;
&#xD;
          -  Active, second malignancy oder remission after second malignancy &lt; 5 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christof Rottenburger, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Damian Wild, Prof Dr Dr</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christof Rottenburger, Dr. med.</last_name>
    <phone>0041613286551</phone>
    <email>Christof.Rottenburger@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Damian Wild, Prof Dr Dr</last_name>
    <phone>0041613286683</phone>
    <email>damian.wild@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Basel, Clinic for radiology and nuclear medicine</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christof Rottenburger, Dr. med.</last_name>
      <phone>0041613286551</phone>
      <email>christof.rottenburger@ubs.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>https://www.unispital-basel.ch/en</url>
    <description>Homepage University Hospital Basel</description>
  </link>
  <reference>
    <citation>Sauter AW, Mansi R, Hassiepen U, Muller L, Panigada T, Wiehr S, Wild AM, Geistlich S, Béhé M, Rottenburger C, Wild D, Fani M. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog (177)Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution? J Nucl Med. 2019 Mar;60(3):393-399. doi: 10.2967/jnumed.118.207845. Epub 2018 Jul 12.</citation>
    <PMID>30002107</PMID>
  </reference>
  <reference>
    <citation>Rottenburger C, Nicolas GP, McDougall L, Kaul F, Cachovan M, Vija AH, Schibli R, Geistlich S, Schumann A, Rau T, Glatz K, Behe M, Christ ER, Wild D. Cholecystokinin 2 Receptor Agonist (177)Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study. J Nucl Med. 2020 Apr;61(4):520-526. doi: 10.2967/jnumed.119.233031. Epub 2019 Sep 13.</citation>
    <PMID>31519804</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>February 19, 2014</study_first_submitted>
  <study_first_submitted_qc>March 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2014</study_first_posted>
  <last_update_submitted>August 3, 2020</last_update_submitted>
  <last_update_submitted_qc>August 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Calcitonin</keyword>
  <keyword>Medullary thyroid carcinoma</keyword>
  <keyword>Peptide receptor radionuclide therapy</keyword>
  <keyword>Gastrin</keyword>
  <keyword>Cholecystokinin-2 receptor</keyword>
  <keyword>Neuroendocrine tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecystokinin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

